Saturday, August 16, 2025

Latest

Champignon Brands Appoints Dr Joseph Gabriele To Special Advisory Committee

Champignon Brands (CSE: SHRM) this morning announced that it is bolstering its special advisory committee through the appointment of Dr Joseph Gabriele, a molecular pharmacologist specializing in signal transduction within the central nervous system.

Gabriele is expected to be responsible for championing Champignon’s development and commercialization of rapid onset treatments which are capable of improving health outcomes. The special advisory committee as a whole is expected to evaluate potential positive effects that its medicinal mushroom formulations may have on individuals suffering from depression or post traumatic stress disorder, as well as substance and alcohol use disorders.

Gabriele himself is specialized in molecular pharmacology, transdermal delivery, and formulation chemistry with pharmaceutical, natural molecules. Most recently he lead Delivra, which was later acquired by Harvest One Cannabis (TSXV: HVT), where he developed a transdermal delivery platform that can be tailored to deliver drugs via the skin to the skin derma, circulatory system, or muscles.

Dr. Gabriele’s established research credentials, entrepreneurial nature and relentless pursuit of medical innovation represents the desired skill sets that Champignon needs as we accelerate our accession into the psychedelic medicine arena. The appointment of Dr. Gabriele equips us with both a celebrated medical researcher, as well as a seasoned CPG formulation specialist, which will allow for the continued development of our mushroom-infused health products, novel delivery systems and eventual drug discovery initiatives.

Gareth Birdsall, CEO of Champignon Brands

Champignon Brands last traded at $0.30 on the CSE.


FULL DISCLOSURE: Champignon Brands is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Champignon Brands on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Eldorado Gold Q2: Free Cash Flow Funds Development

SSR Mining Q2 Earnings: Cripple Creek Nearly Pays For Itself

Gold’s Next 12 Months Will Be the Trade of a Lifetime | Simon Marcotte – Northern Superior

Recommended

First Majestic Posts Record Free Cash Flow In Second Quarter

Silver47 Identifies 35 Mineralized Prospects Across 55 Km Trend At Red Mountain

Related News

Champignon Brands Signs Definitive Agreement To Acquire AltMed Capital

Champignon Brands (CSE: SHRM) has announced this evening that it will be acquiring alternative medicine...

Thursday, April 9, 2020, 09:03:04 PM

Champignon Brands Announces Contract Research Partner For Ketamine, Psilocybin IP Portfolio

Champignon Brands (CSE: SHRM) announced this morning that it is advancing its drug discovery program...

Monday, June 8, 2020, 10:03:37 AM

Champignon Brands To Acquire Psilocybin Research Firm Tassili Life Sciences

Last night, Champignon Brands (CSE: SHRM) announced that they have signed a definitive agreement to...

Saturday, March 28, 2020, 01:12:34 PM

Braxia Scientific Launches Multiple-Dose Psilocybin Clinical Trial for Treatment-Resistant Depression

Braxia Scientific Corp. (CSE: BRAX), formerly Champignon Brands, announced today that its clinical research and...

Friday, August 27, 2021, 08:20:00 AM

Champignon Brands To Acquire Biotech Firm Novo Formulations

Champignon Brands (CSE: SHRM) announced today that they have signed a definitive agreement to acquire...

Thursday, March 19, 2020, 03:27:32 PM